EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer – A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial

Kathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christoph Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann und 7 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2025.116133 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Kathrin Heinrich und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; …. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Cetuximab, Bevacizumab. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck KGaA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsCetuximabBevacizumabCamptothecinProto-Oncogene Proteins B-rafHumansMaleFemaleLeucovorinFluorouracilMiddle AgedSex FactorsAgedAdultras Proteins

Stichwörter der Autor:innen

Anti-EGFRCetuximabColorectal cancerGenderSex

Substanzen

LeucovorinCetuximabFluorouracilBevacizumabCamptothecinProto-Oncogene Proteins B-rafBRAF protein, humanras Proteins

Autor:innen und Institutionen

  • Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany; Comprehensive Cancer Center, University Hospital (LMU), Munich, German…
  • Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; German Cancer Cons…
  • Gesundheitszentrum St. Marien, Amberg, Germany.
  • Onkologie Ravensburg, Ravensburg, Germany.
  • Department of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, and Comprehensive Cancer Center Erlangen EMN, Erlangen, Germany.
  • Oncological Practice, Landshut, Germany.

Förderung

  • Merck KGaA

Zitieren

APA

Heinrich, K., Stintzing, S., Weikersthal, L. F. V., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S. E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Moehler, M., Scheithauer, W., Jung, A., Holch, J. W., Held, S., Modest, D. P., & Heinemann, V. (2026). Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer – A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116133

Vancouver

Heinrich K, Stintzing S, Weikersthal LFV, Decker T, Kiani A, Kaiser F, et al. Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer – A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2025.116133

BibTeX
@article{Heinrich2026,
  author = {Heinrich, Kathrin and Stintzing, Sebastian and Weikersthal, Ludwig Fischer von and Decker, Thomas and Kiani, Alexander and Kaiser, Florian and Al-Batran, Salah-Eddin and Heintges, Tobias and Lerchenmüller, Christoph and Kahl, Christoph and Seipelt, Gernot and Kullmann, Frank and Moehler, Markus and Scheithauer, Werner and Jung, Andreas and Holch, Julian W and Held, Swantje and Modest, Dominik Paul and Heinemann, Volker},
  title = {Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer – A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2025.116133}
}
Kostenlos starten →